• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eitan Medical’s Sapphire infusion pump recall is Class I

December 1, 2023 By Sean Whooley

Eitan Medical Sapphire Multi-Therapy infusion pump
The Sapphire multi-therapy infusion pump. [Image from Eitan Medical]
The FDA determined that the recall of certain Eitan Medical Sapphire infusion pumps is Class I, the most serious kind.

Netanya, Israel-based Eitan recalled certain Sapphire pumps running software version Rev 16.10. The recall includes the Sapphire multi-therapy pump, the Sapphire Epidural pump and the Sapphire Plus pump. Eitan initiated the recall on Sept. 11, 2023, and it affected 1,383 devices in the U.S.

According to an FDA notice, the company recalled the pumps due to software issues with version Rev 16.10. Pumps with this software version may fail to detect air in the line when running on battery power. In some cases, the pump may not sound an alarm when air enters the line. Failure to detect air in the line can lead to a blockage in a blood vessel (embolism). That could lead to unstable blood pressure, stroke, heart attack or even death.

To date, Eitan reports no injuries or deaths associated with this issue.

Eitan instructed customers to cease use of the recalled pumps on battery power. Users should connect the devices to a power supply, like continuous AC power. They should also add an air-eliminating filter to the device.

According to the FDA, the company no longer offers the affected software version. The company intends to provide a new software update correcting the problem in four months.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Technology Tagged With: Eitan Medical, FDA

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS